{"analyses":[{"ciLowerLimit":"0.013","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.960","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.016","paramType":"Hazard Ratio (HR)","paramValue":"0.111","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The median DOCB was not reached in Arm A and the 95% CI was not available due to insufficient numbers of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median DOCB was not reached in Arm B and the upper confidence limit was not available due to insufficient numbers of participants with events.","groupId":"OG001","lowerLimit":"3.38","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Time from first evidence of confirmed assessment of sCR, CR, VGPR, PR, or MR to first confirmed disease progression, or to death due to any cause. DOCB is defined only for patients with a confirmed MR or better.","dispersionType":"95% Confidence Interval","groups":[{"description":"Treatment was given in 28-day cycles in an outpatient treatment setting.\n\n* Melflufen 30 mg intravenous (i.v.) infusion on Day 1 of each cycle\n* Dexamethasone 40 mg per oral (p.o.) weekly (20 mg p.o. weekly if ≥75 years)\n* Daratumumab 1800 mg subcutaneously (s.c.) on Days 1, 8, 15, and 22 in Cycles 1 and 2, on Days 1 and 15 in Cycles 3 to 6, and on Day 1 from Cycle 7","id":"OG000","title":"Arm A (Melflufen+Dexamethasone+Daratumumab)"},{"description":"Treatment was given in 28-day cycles in an outpatient treatment setting.\n\n• Daratumumab 1800 mg s.c. on Days 1, 8, 15, and 22 in Cycles 1 and 2, on Days 1 and 15 in Cycles 3 to 6, and on Day 1 from Cycle 7","id":"OG001","title":"Arm B (Daratumumab)"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed using the Full Analysis Set (FAS).","reportingStatus":"POSTED","timeFrame":"From the date of randomization until the end of study (approximately 12 months).","title":"Duration of Clinical Benefit (DOCB)","type":"SECONDARY","unitOfMeasure":"months"}